Lilly Looks For Sepsis Biomarkers That Could Aid Xigris Administration
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies are underway to support the use of protein C as a biomarker, Lilly Senior Medical Director for Cardiovascular & Acute Care Macias tells a recent CDER seminar. Data suggest Xigris, a form of activated protein C, has higher survival rates when administered early. Biomarkers could be a signal for use.
You may also be interested in...
Lilly Xigris Trial Will Use Biomarker To Tailor Treatment
Partner Biosite will develop a rapid protein C diagnostic to be used in the Phase IIb trial, which is set to begin in the fourth quarter of 2006.
Lilly Xigris Trial Will Use Biomarker To Tailor Treatment
Partner Biosite will develop a rapid protein C diagnostic to be used in the Phase IIb trial, which is set to begin in the fourth quarter of 2006.
Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial
Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.